What We're Reading: Page 188
Industry reads hand-picked by our editors
May 15, 2020
-
Bloomberg
Novartis CEO Says Covid-19 Vaccine May Take Until End of 2021
-
Kyodo News
Japan's health insurance to cover $1.5 million gene therapy drug
-
The Wall Street Journal
Why Big Investors Aren’t Betting It All on a Coronavirus Cure
-
STAT
FDA says Abbott’s 5-minute Covid-19 test may miss infected patients
May 14, 2020
-
STAT
Biotech’s new top lobbyist is a social justice advocate. Will industry listen?
-
Science
Emails offer look into whistleblower charges of cronyism behind potential COVID-19 drug
-
Bloomberg
Sanofi CEO's Remarks on Vaccine Plans Stir Outrage in France
-
POLITICO
White House to tap former pharmaceutical exec as 'therapeutics czar'
May 13, 2020
-
Bloomberg
French Drug Giant to Give U.S. Preference on Covid Vaccine
-
Science
Unveiling 'Warp Speed,' the White House's America-first push for a coronavirus vaccine
-
C&EN
Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?
-
The New York Times
He Was a Science Star. Then He Promoted a Questionable Cure for Covid-19.
May 12, 2020
-
The Wall Street Journal
Distribution of Key Drug Was Flawed, Says White House Official
-
Endpoints News
Merck to move global headquarters, returning to an old home
-
STAT
Prominent Broad Institute scientist leaves to lead R&D at Genentech
-
Bloomberg
NIH Director Talks Vaccines, Virus Mutation and Clinical Trials
May 11, 2020
-
The New York Times
U.S. to Accuse China of Trying to Hack Vaccine Data, as Virus Redirects Cyberattacks
-
The Wall Street Journal
Amazon, Berkshire, JPMorgan Health-Care Venture Looking for New CEO
-
Reuters
Pfizer to outsource some drug production, focus on coronavirus vaccine
-
Financial Times
Paris, Texas, offers a cautionary tale on reopening America
May 07, 2020
-
STAT
Doctors lambaste process for distributing Covid-19 drug remdesivir
-
The Atlantic
The Problem With Stories About Dangerous Coronavirus Mutations
-
Endpoints News
Tetraphase has two suitors, despite struggling market for antibiotics
-
Reuters
Japan approves Gilead Sciences' remdesivir as COVID-19 drug
Previous
